UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 FORM 20-F/A
 (Amendment No. 1)
 (MARK ONE)
 o
    
    REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934
 OR
 þ
    
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 þ For the fiscal year ended: December 31, 2008
 OR
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from  to
 OR
 o
    
    SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 Date of event requiring this shell company report
 Commission file number: 0-22320
 Trinity Biotech plc
 (Exact name of Registrant as specified in its charter)
 Ireland
 (Jurisdiction of incorporation or organization)
 IDA Business Park, Bray, Co. Wicklow, Ireland
 (Address of principal executive offices)
 Securities registered or to be registered pursuant to Section 12 (b) of the Act:
 Title of each class
    
    Name of each exchange on which registeredAmerican Depository Shares
    
    NASDAQ Stock Market LLC(each representing 4 A Ordinary Shares,par value US$0.0109)
 Securities registered or to be registered pursuant to Section 12(g) of the Act  None
 
 (Title of Class)
 Securities for which there is a reporting obligation pursuant to Section 15 (d) of the Act:
None
 
 (Title of each class)
 Indicate the number of outstanding shares of each of the issuers classes of capital or common
stock as of the close of the period covered by the annual report: 73,601,497 Class A Ordinary
Shares and 700,000 Class B Ordinary Shares.
 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule
405 of the Securities Act.
 Yes o No þ
 If this report is an annual or transition report, indicate by check mark if the registrant is
not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934.
 Yes o No þ
 Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
 Yes þ No o
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer or a non-accelerated filer. See definition of accelerated filer and large accelerated file
in Rule 12b-2 of the Exchange Act:
 Large accelerated filer o
    
    Accelerated filer þ
    
    Non-accelerated filer o
 Indicate by check mark which financial statement item the registrant has elected to follow:
 Item 17 o Item 18 þ
 If this is an annual report, indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).
Yes o No þ
 This Annual Report on Form 20-F is incorporated by reference into our Registration Statements
on Form F-3 File No. 333-113091, 333-112568, 333-116537, 333-103033, 333-107363 and 333-114099 and
our Registration Statements on Form S-8 File No. 33-76384, 333-220, 333-5532, 333-7762 and
333-124384.




---



##### 



EXPLANATORY NOTE
       ITEM 19. EXHIBITS
 Exhibit No.
    
    Description of Exhibit10.1
    
    
    Asset Purchase Agreement among Benen Trading Ltd., Cortex Biochem, Inc. and
the shareholders of Cortex Biochem, Inc., dated September 4, 200710.2
    
    
    Acquisition Agreement between Trinity Biotech (UK Sales) Limited and Ken
Frizelle, Trevor Frizelle, Kevin Frizelle, James Frizelle and Dianne Frizelle
trading in partnership as Sterilab Services, dated October 4, 200712.1
    
    
    Certification by Chief Executive Officer Pursuant to Section 302 of the
Sarbanes- Oxley Act of 2002.(1)12.2
    
    
    Certification by Chief Financial Officer Pursuant to Section 302 of the
Sarbanes- Oxley Act of 2002.(1)13.1
    
    
    Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.(1)13.2
    
    
    Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.(1)15.1
    
    
    Consent of Independent Registered Public Accounting Firm (KPMG).(1)
 
 (1)
    
    Previously filed with the Companys Form 20-F for the year ended December 31, 2008.




---



##### 



SIGNATURES
  TRINITY BIOTECH PLCBy:

/s/ Ronan OCaoimhMr. Ronan OCaoimhDirector/
Chief Executive Officer



Date: March 4, 2010By:
    /s/ Kevin TansleyMr. Kevin TansleyCompany Secretary/
Chief Financial Officer
Date: March 4, 2010